Applied regulatory science and evidence-based policy inputs
Our work drives regulatory innovation and is centered on developing robust, evidence-based policy inputs for the rapidly evolving biotech landscape.
We invite academic, industry, and governmental partners to collaborate on research that shapes regulatory outcomes and policy implementation.
Collaborate on ResearchOur research is disseminated across journal articles, policy briefs, foundational books, and practical case studies.
1st Edition - June 1, 2025
Academic Foundation, New Delhi and ISEAS, Singapore. 2004
Astral Publications Delhi, 300pp
in Environmental Safety of Biotech and IPM Technologies, CABI. 2012
in Cotton, Biotechnology in Agriculture and Forestry, Springer. 2010
Melanoma Research (Accepted). [Q2, IF 1.9]
Nat. HSS Communications (Accepted). [Q1, IF 3.7]
Tropical Parasitology, 15(2): 71–80. [Q3, IF 1.0]
Infectious Microbes & Diseases, 10-1097. [Q3, IF 1.8]
Int. J. Medical Informatics, 205:10611. [Q1, IF 4.0]
Health Security, 23(4):230–241. [Q1, IF 2.1]
Health Security, 23(4):282–288. [Q1, IF 2.1]
Tropical Animal Health & Production, 57(6). [Q2, IF 1.7]
3 Biotech, 15:170. [Q1, IF 2.9]
The Lancet Global Health, 13(7):e1170–e1171. [Q1, IF 19.9]
The Lancet Global Health, 13(6):e986–e987. [Q1, IF 19.9]
Journal of Cancer Policy, 43:100521. [Q2, IF 2.0]
Frontiers in AI, 7:1372161. [Q2, IF 3.0]
Pharma focus Asia Issue 54 pages 13
Journal of Biosafety and Biosecurity 6 (2024) 223–224
Royal Society of Chemists (RSC Adv.), 2024, 14, 25130-25148
The Lancet Regional Health - Southeast Asia, (2024) Volume 27, 100447
Cell Stress Chaperones. 2022 May;27(3):189-195. (IF:3.7)
Microbial Pathogenesis 158: 105057, 2021 Jun 18 (IF: 3.8)
Frontiers Public Health 9:673536. doi:10.3389/fpubh.2021.673536 (IF: 3.5)
IUBMB Life, 2020; 72(12):2533-2545. (IF: 3.9, 12 Citations)
Regulatory support for ICMR sponsored clinical trial - Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity, and Lot-to-Lot consistency of BBV152, a Whole virion Inactivated SARS-CoV-2 Vaccine in Adults greater than or equal to 18 Years of Age.
A Prospective, multicentre, Phase II Seamlessly Followed by Phase III Clinical Study to Evaluate the Immunogenicity and Safety of Biological E's CORBEVAX Vaccine for Protection Against COVID-19 Disease When Administered to COVID-19-Negative Adult Subjects.
Regulatory support for CAR-T Cell therapy to M/s Immuneel Therapeutics Private Limited for guidance on documents, filings from licenses to IND applications/approvals.
Agreement between Genomeks, a Genomics Division of Enviromax LLP, Hyderabad for Analyzing and preparing of Detailed Project Report (DPR) on the Emerging Cell and gene therapy business plan Landscape in India.
Collaboration with Deloitte USA with support from Department of State, USA, to host an event called "The India Biosecurity Fellow Program, a collaborative capacity building initiative. This three-day program marked a significant milestone as the first of its kind in India, training 15 young professionals.
Collaboration with Gryphon Scientific LLC, a US-based research consultancy organization working on global health and security to host an event called "Cybersecurity Needs for the Indian Biotechnology Sector" (In-person workshop) With funding from US Department of State Cooperative Threat Reduction Office.
Established MGM Clinical Trial & Training Centre (MGM-CTC) with infrastructure, human resource and data center. Coordinate the sponsored clinical trials both at MGMCRI and SSMCRI and other constituent college and centers.
Comprehensive training programs covering risk assessment, containment, decontamination, security protocols, and incident reporting for biological agents handling.
Connect with us to learn more about our research initiatives and collaboration opportunities.
Get In Touch